Navigation Links
For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
Date:4/2/2013

BURLINGTON, Mass., April 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European rheumatologists indicate that new therapies for the treatment of systemic lupus erythematosus (SLE), that can positively differentiate themselves from current therapies in their effect on disease activity, would be well received by physicians and would be poised to benefit from strong uptake. Based on currently available clinical data and thought leader opinion, the emerging therapies epratuzumab (Immunomedics/UCB) and Lupuzor (ImmuPharma's forigerimod, P140, CEP-33457) have the potential to offer improvements over IV belimumab (Human Genome Sciences/GlaxoSmithKline's Benlysta) in reducing disease activity. Thought leaders perceive belimumab to offer only modest efficacy benefits in patients who are refractory to conventional immunosuppressants.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

According to the DecisionBase 2013 report entitled Which Clinical Attributes Will Most Effectively Position Emerging Biologics Against IV Belimumab in the Moderate to Severe Patient Segment?, clinical data and thought leader opinion suggest that Anthera Pharmaceuticals' blisibimod also shows potential to more effectively reduce disease activity than IV belimumab in the severe SLE patient segment.

"Interviewed thought leaders consistently indicate a need for drugs with greater efficacy on disease activity, noting a variety of issues with currently available therapies," said Decision Resources Analyst Laura Croal , Ph.D. "In the case of newest approved agent, IV belimumab, the efficacy benefit in moderate to severe SLE is p
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... YORK, March 31, 2011 Intercept Pharmaceuticals, Inc., today ... double-blind  Phase II clinical trial of obeticholic acid (OCA) ... (PBC).  The study evaluated the effects of 10 mg ... patients with elevated alkaline phosphatase (AP).  AP is a ...
... Services Corp., a leading provider of pharmaceutical product ... of Dean Shirazi, Ph.D., to Vice President, Analytical ... 4, 2011. (Logo:   https://photos.prnewswire.com/prnh/20110330/CG74146LOGO ) ... in June 1992 as a Senior Scientist, has ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 3AAIPharma Services Announces Promotion of Dean Shirazi 2
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... work commitment is a big reason why, new research suggests. ... Mathias Basner, an assistant professor of sleep and chronobiology in ... A time-use survey of nearly 125,000 Americans, ages 15 ... exchanged for sleep. Short sleepers -- those who slept six ...
(Date:12/15/2014)... Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first full-time ... providing evidence on the impact of 100% pure fruit ... enough evidence already exists showing a negative link between ... the onset of tooth decay. One question that has ... fruit juice, meaning it is completely natural with no ...
(Date:12/15/2014)... Health Dialog, a leading provider ... it has received Patient Oriented Accreditation from the ... Disease Management (DM) Programs for asthma, congestive heart ... disease and diabetes. This marks the 12th continuous ... Disease Management (DM) Programs, reaffirming Health Dialog’s focus ...
(Date:12/15/2014)... 15, 2014 Kathy McAfee, America's Marketing ... World Awards in the category of Best Blog 2014. ... for her weekly career blog Networking Ahead ... help professionals elevate their talent and influence through better ... after her book Networking Ahead for Business, has been ...
(Date:12/15/2014)... Ontario (PRWEB) December 15, 2014 Bacteroides is ... Not only is it much more prevalent than coliforms, it ... replicate in the environment. , Key Benefits of the ... for fecal contamination , Eliminates false positives from ... Specificity and Sensitivity , Maintain the same ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... N.C., Feb. 5 Many leading companies have ... various reasons, but in times of economic adversity, ... functions within companies are being questioned. Although internal ... purpose, these organizations often grow and take on ...
... Republic of The Gambia has decided to create a ... (Iniciaci sense mutilaci), directed by UAB researcher Adriana Kaplan, ... Institute of Primary Care Research IDIAP Jordi Gol and ... eliminate the genital lesions created by these traditional rituals ...
... (CMC) has,selected Surgical Information Systems (SIS) to be ... in Scranton, PA. , ... CMC chose the SIS Solution ... and operational efficiencies in the surgery department.,In addition ...
... Minutes Without Side Effects or PillsPHOENIX and SCOTTSDALE, ... specialist Morton I. Hyson, M.D., will announce a ... according to Clinical Topicals PHP. The treatment works ... or contraindications ( www.HysonHeadache.com ). After a decade ...
... preventing cystic fibrosis lung disease in an animal model by ... the first therapy to successfully attack the root cause of ... mice are given inhalation treatment with the drug in the ... lungs and airway inflammation and chronic lung damage can be ...
... Barcode Point-of-Care Patient Safety Solution-SAN DIEGO, Feb. 5 ... barcode point-of-care (BPOC) solutions to hospitals, today announced ... is now being used by 55 U.S. hospitals. ... to go live with the IntelliDOT System on January ...
Cached Medicine News:Health News:New Study Provides Benchmarks for Best Practices for Valuing Internal Consulting Organizations 2Health News:Gambia takes on as National Program UAB project to abolish FGM 2Health News:Gambia takes on as National Program UAB project to abolish FGM 3Health News:Community Medical Center (Scranton) Selects SIS Perioperative Solution 2Health News:Neurologist to Announce Breakthrough Headache Treatment 2Health News:Hope for preventative treatment for cystic fibrosis lung disease 2Health News:Hope for preventative treatment for cystic fibrosis lung disease 3Health News:IntelliDOT Bedside Medication Administration(TM) Goes Live at 55th Hospital 2Health News:IntelliDOT Bedside Medication Administration(TM) Goes Live at 55th Hospital 3Health News:IntelliDOT Bedside Medication Administration(TM) Goes Live at 55th Hospital 4
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
S.O.C. Medium...
... rHead Radial Implant System provides todays ... to radial head replacement. Modular ... patient anatomy while minimizing ligamentous and ... designed alignment guide assists in both ...
Medicine Products: